Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nair, S.
Right arrow Articles by Henry, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nair, S.
Right arrow Articles by Henry, M. T.
(Chest. 2005;128:48-54.)
© 2005 American College of Chest Physicians

A Randomized Controlled Trial To Assess the Optimal Dose and Effect of Nebulized Albuterol in Acute Exacerbations of COPD*

Suresh Nair, MBBS; Enson Thomas, MBBS; Stanley B. Pearson, DPhil, DM and Michael T. Henry, MSc, MD

* From the Department of Respiratory Medicine, Leeds General Infirmary, Great George Street, Leeds, West Yorkshire, UK.

Correspondence to: Michael Henry, MSc, MD, Department of Respiratory Medicine, Leeds General Infirmary, Leeds LS1 3EX, UK; e-mail: michael.henry{at}leedsth.nhs.uk

Study objectives: Despite the widespread use of short-acting, inhaled ß2-agonists in acute exacerbations of COPD (AECOPDs), little is known about their optimal dose. The aims of this study are to compare the bronchodilator response to incremental doses of inhaled albuterol during and after recovery from an AECOPD, and to compare the effects of regular nebulized albuterol, 2.5 mg and 5 mg, on the speed of recovery.

Methods: Eighty-six patients admitted with an AECOPD were recruited. Each patient was administered incremental doses of inhaled albuterol on hospital admission and following recovery. Dose-response curves were constructed based on FEV1 and peak expiratory flow rate (PEFR) recorded after each incremental dose. Patients were then randomized in a double-blind fashion to receive 2.5 mg or 5 mg of nebulized albuterol q4h until recovery. Twice-daily PEFR, the number of extra doses of bronchodilators, and side effects reported were recorded.

Results: Maximal bronchodilation (Emax) FEV1 (maximal bronchodilatory response to albuterol) increased from 0.64 ± 0.27 L/min during the exacerbation to 0.94 ± 0.38 L/min during recovery (p < 0.001). The Emax PEFR increased from 147.53 ± 62.46 L/min to 222.94 ± 73.82 L/min after recovery (p = <0.001). There was no significant difference in rate of recovery of PEFR (p = 0.684), duration of hospital stay (p = 0.084), or side effects (p = 0.506) between the groups receiving 2.5 mg or 5 mg of nebulized albuterol.

Conclusions: There was significant improvement in Emax to inhaled albuterol as the COPD exacerbation resolved. There was no significant difference in outcomes including length of hospital stay or recovery of lung function between patients treated with regular 2.5 mg vs 5 mg of nebulized albuterol during an AECOPD.

Key Words: acute exacerbation • albuterol • ß2-agonists • COPD • dose response






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.